R-7050 (Synonyms: TNF-α Antagonist III) |
| Catalog No.GC11659 |
R-7050 is a novel cell-permeable triazoloquinoxaline compound that selectively inhibited TNF-α induced cellular signaling.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 303997-35-5
Sample solution is provided at 25 µL, 10mM.
R-7050 is a novel cell-permeable triazoloquinoxaline compound that selectively inhibited TNF-α induced cellular signaling[2].
In RBL-2H3 cells R-7050 significantly reduced TNF proliferation when autophagy was also inhibited by Baf-A1[7].CA to reduce cell viability in MDA-MB-231 breast cancer cells and tumorigenic HEK 293 cells but not in normal NIH3T3 fibroblast cells. Abundance of TNFA, TNF Receptor 1 (TNFR1) and cleaved caspase-8/-3 proapoptotic proteins to increase with CA treatment. Blocking of TNFA-TNFR1 signalling by small molecule inhibitor, R-7050, reduced the expression of cleaved caspase-8 and caspase-3 at the protein level[3]. TRPA1 channel was positively expressed in the cell bodies and processes of HODs. The expression TRPA1 channel was significantly up-regulated by high concentration of TNF-α, which could be suppressed by R-7050[5].
A single administration of R-7050 reduced neurovascular injury after ICH. In contrast to biologic approaches that directly bind and neutralize TNF-α activity, R-7050 selectively inhibits the association of TNFR with intracellular adaptor molecules, such as TRADD and RIP1, limiting receptor internalization and preventing subsequent cellular responses after TNF-α binding[1]. Capsaicin, a selective TRPV1 agonist, increased ipsilateral afferent renal nerve activity in WT but not TRPV1-/- mice. WD intake increased leptin, IL-6, and TNF-α in adipose tissue, and TNF-α antagonist III, R-7050, decreased leptin in TRPV1-/--WD. The urinary albumin level was higher in TRPV1-/--WD than WT-WD[4]. Treatment with the TNF receptor-1 inhibitor R-7050 during nephrotoxic serum nephritis reduced damage, fibrosis, and necroptosis in wild-type mice and mice with KLF4-deficient macrophages, and abrogated the differences between the two groups in these parameters[6].
References:
[1]. King MD, Alleyne CH Jr,et,al. TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice. Neurosci Lett. 2013 May 10;542:92-6. doi: 10.1016/j.neulet.2013.02.051. Epub 2013 Mar 7. PMID: 23499961; PMCID: PMC3744337.
[2]. Gururaja TL, Yung S, et,al. A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1. Chem Biol. 2007 Oct;14(10):1105-18. doi: 10.1016/j.chembiol.2007.08.012. PMID: 17961823.
[3]. Pal A, Tapadar P, Pal R. Exploring the Molecular Mechanism of Cinnamic Acid-Mediated Cytotoxicity in Triple Negative MDA-MB-231 Breast Cancer Cells. Anticancer Agents Med Chem. 2021;21(9):1141-1150. doi: 10.2174/1871520620666200807222248. PMID: 32767960.
[4]. Zhong B, Ma S, et,al. Ablation of TRPV1 Elevates Nocturnal Blood Pressure in Western Diet-fed Mice. Curr Hypertens Rev. 2019;15(2):144-153. doi: 10.2174/1573402114666181031141840. PMID: 30381083; PMCID: PMC6635649.
[5]. Liu J, Que K, et,al. Tumor Necrosis Factor-α Regulates the TRPA1 Expression in Human Odontoblast-Like Cells. J Pain Res. 2020 Jul 6;13:1655-1664. doi: 10.2147/JPR.S255288. PMID: 32753941; PMCID: PMC7352379.
[6]. Wen Y, Lu X, et,al. KLF4 in Macrophages Attenuates TNFα-Mediated Kidney Injury and Fibrosis. J Am Soc Nephrol. 2019 Oct;30(10):1925-1938. doi: 10.1681/ASN.2019020111. Epub 2019 Jul 23. PMID: 31337692; PMCID: PMC6779357.
[7]. Ayo TE, Adhikari P, et,al. TNF Production in Activated RBL-2H3 Cells Requires Munc13-4. Inflammation. 2020 Apr;43(2):744-751. doi: 10.1007/s10753-019-01161-4. PMID: 31897916; PMCID: PMC7176528.
| Kinase experiment [1]: | |
|
Preparation Method |
A549 cells plated. The next day, compound library(including R-7050) prepared were added at a final concentration of 10 μM in 0.2% (v/v) DMSO. Cells were preincubated with compounds for 1 hr prior to a 4 hr stimulation with either TNFα or IL-1β. |
|
Reaction Conditions |
10 μM R-7050 and cell for 1h |
|
Applications |
In TNFα-induced ICAM-1 expression, R-7050 inhibition potency (EC50 = 0.63 μM) was 2- to 3-fold greater than EC50 for IL-1β-induced ICAM-1 expression (1.45 μM). |
| Cell experiment [2]: | |
|
Cell lines |
Wild-type RBL-2H3 cells |
|
Preparation Method |
Wherever indicated, 6.7 μM of R-7050 (dissolved in DMSO) or 0.1 μM of bafilomycin A1 was added along with anti-TNP IgE during sensitization. |
|
Reaction Conditions |
6.7 μM R-7050 |
|
Applications |
R-7050 significantly reduced TNF proliferation when autophagy was also inhibited by Baf-A1. |
| Animal experiment [3]: | |
|
Animal models |
Male CD-1 mice (8–10 weeks old) |
|
Preparation Method |
R-7050 (6–18 mg/kg) was administered via intraperitoneal route at the time of injury or up to 2 h post-ICH. |
|
Dosage form |
6–18 mg/kg R-7050 for 0.5-2h |
|
Applications |
R-7050 attenuates neurovascular injury after ICH. |
|
References: [1]. Gururaja TL, Yung S, Ding R, Huang J, Zhou X, McLaughlin J, Daniel-Issakani S, Singh R, Cooper RD, Payan DG, Masuda ES, Kinoshita T. A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1. Chem Biol. 2007 Oct;14(10):1105-18. doi: 10.1016/j.chembiol.2007.08.012. PMID: 17961823. [2]. Ayo TE, Adhikari P, et,al. TNF Production in Activated RBL-2H3 Cells Requires Munc13-4. Inflammation. 2020 Apr;43(2):744-751. doi: 10.1007/s10753-019-01161-4. PMID: 31897916; PMCID: PMC7176528. [3]. King MD, Alleyne CH Jr, Dhandapani KM. TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice. Neurosci Lett. 2013 May 10;542:92-6. doi: 10.1016/j.neulet.2013.02.051. Epub 2013 Mar 7. PMID: 23499961; PMCID: PMC3744337. |
|
| Cas No. | 303997-35-5 | SDF | |
| Synonyms | TNF-α Antagonist III | ||
| Chemical Name | 8-chloro-4-(phenylthio)-1-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline | ||
| Canonical SMILES | ClC1=CC(N2C3=NN=C2C(F)(F)F)=C(C=C1)N=C3SC4=CC=CC=C4 | ||
| Formula | C16H8ClF3N4S | M.Wt | 380.8 |
| Solubility | DMSO (warmed with 50ºC water bath) 9 mg/mL (23.64 mM) ; DMF: 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6261 mL | 13.1303 mL | 26.2605 mL |
| 5 mM | 525.2 μL | 2.6261 mL | 5.2521 mL |
| 10 mM | 262.6 μL | 1.313 mL | 2.6261 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *